Xenon Pharmaceuticals INC Form 4 insider transactions

Xenon Pharmaceuticals Inc. Director Dawn Svoronos has increased her beneficial ownership in the company by acquiring 17,012 stock options and 2,645 restricted share units (RSUs) on June 5, 2025.

Director Steven Gannon exercised stock options to acquire 5,144 common shares of Xenon Pharmaceuticals at $12.57 per share on May 14, 2025.

CEO Ian Mortimer reports acquisition of share options and restricted share units in Xenon Pharmaceuticals.

Chief Medical Officer Christopher John Kenney reports acquisition of share options and restricted share units in Xenon Pharmaceuticals Inc.

Andrea DiFabio, Chief Legal Officer of Xenon Pharmaceuticals, reports acquisition of share options and restricted share units.

Xenon Pharmaceuticals' CEO, Ian Mortimer, exercised stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Xenon Pharmaceuticals' Chief Financial Officer, Sherry Aulin, executed multiple transactions involving the exercise of stock options and subsequent sale of shares on December 18, 2024.

Xenon Pharmaceuticals director Gary Patou exercised stock options and sold shares on November 22, 2024, resulting in a net decrease in his direct holdings.

Director Gary Patou of Xenon Pharmaceuticals Inc. was granted stock options exercisable for 15,542 common shares on June 5, 2024.

Patrick Machado, a director at Xenon Pharmaceuticals, acquired stock options for 15,542 common shares on June 5, 2024, according to a recent SEC filing.

Director Justin D. Gover acquired stock options in Xenon Pharmaceuticals, according to a recent SEC filing.

Elizabeth A. Garofalo, a director of Xenon Pharmaceuticals Inc., acquired stock options exercisable for 15,542 common shares on June 5, 2024.

Director Steven Gannon acquired stock options in Xenon Pharmaceuticals, signaling a potential increase in his stake in the company.

Director Gillian Cannon acquired stock options in Xenon Pharmaceuticals, according to a recent SEC Form 4 filing.

Dawn Svoronos, a director at Xenon Pharmaceuticals Inc., acquired stock options for 15,542 common shares on June 5, 2024.

Christopher Von Seggern, Chief Commercial Officer of Xenon Pharmaceuticals Inc., was granted stock options for 100,000 common shares on March 11, 2024.

Sherry Aulin, CFO of Xenon Pharmaceuticals, was granted stock options for 100,000 common shares on March 11, 2024, vesting over a three-year period.

Christopher Kenney, Chief Medical Officer of Xenon Pharmaceuticals, was granted stock options for 100,000 common shares on March 11, 2024.

James R. Empfield, EVP of Drug Discovery at Xenon Pharmaceuticals, was granted stock options for 65,000 common shares on March 11, 2024.

Robin Sherrington, EVP of Strategy & Innovation at Xenon Pharmaceuticals, acquired 65,000 stock options on March 11, 2024, according to a Form 4 filing.

Andrea DiFabio, Chief Legal Officer of Xenon Pharmaceuticals, was granted stock options for 100,000 common shares on March 11, 2024, according to a Form 4 filing.

Ian Mortimer, President and CEO of Xenon Pharmaceuticals, was granted stock options for 250,000 common shares on March 11, 2024.

Director Elizabeth A. Garofalo exercised stock options and sold common shares of Xenon Pharmaceuticals Inc. on March 8, 2024.

EVP Robin Sherrington exercised stock options and sold shares of Xenon Pharmaceuticals on March 7, 2024.

Director Steven Gannon of Xenon Pharmaceuticals Inc. (XENE) sold a total of 13,000 common shares on March 7, 2024, at prices ranging from $46.2012 to $46.45.